Csl Behring
Clinical trials sponsored by Csl Behring, explained in plain language.
-
Hizentra study for Post-COVID POTS ends early
Disease control TerminatedThis study tested a medicine called Hizentra (IgPro20) to see if it could help people with post-COVID POTS, a condition that causes a fast heart rate and dizziness when standing up. The trial was stopped early and included 16 adults who had POTS symptoms starting within 4 months …
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Blood clotting drug studied to save lives in trauma bleeding
Disease control TerminatedThis study tested a medicine called BE1116 (a 4-factor prothrombin complex concentrate) to see if it could help people with severe bleeding from traumatic injuries survive. The trial included over 1,300 participants who were expected to need large blood transfusions. The study wa…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Dermatomyositis drug trial halted early – what we learned
Disease control TerminatedThis study tested a weekly injection of Hizentra® (a concentrated antibody solution) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. The goal was to see if it could improve muscle and skin symptoms better than a placebo. The trial was sto…
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 11, 2026 20:37 UTC